Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raludotatug deruxtecan + paclitaxel
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Raludotatug deruxtecan + paclitaxel** is an investigational drug combination comprising raludotatug deruxtecan—a first-in-class CDH6-directed antibody-drug conjugate (ADC) using Daiichi Sankyo's DXd ADC technology—and paclitaxel, a well-established cytotoxic chemotherapeutic agent. Raludotatug deruxtecan consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a tetrapeptide-based cleavable linker. Paclitaxel inhibits microtubule disassembly during cell division, leading to cell cycle arrest and apoptosis. The combination is under investigation for patients with platinum-resistant ovarian cancer and related gynecological tumors, including those previously treated with platinum-based chemotherapy. Development is led by Daiichi Sankyo and Merck, with clinical evaluation in phase 1b/2 trials for relapsed high-grade serous ovarian cancer and related indications[1][2][3][7][9].
- Other names
- R-DXd + paclitaxel
02
Targets
TOP1 (DNA Topoisomerase I)CDH6 (Cadherin-6)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on raludotatug deruxtecan + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raludotatug deruxtecan + paclitaxel.